Association of positive direct antiglobulin test (DAT) with nonreactive eluate and drug-induced immune hemolytic anemia (DIHA).


Journal

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 18 08 2020
revised: 09 11 2020
accepted: 11 11 2020
pubmed: 6 12 2020
medline: 15 10 2021
entrez: 5 12 2020
Statut: ppublish

Résumé

Drug-induced immune hemolytic anemia is a rare condition that occurs primarily because of drug-induced antibodies, either dependent or independent and positive direct antiglobulin test. Our aim was to evaluate the association of positive DAT with nonreactive eluate and DIHA. From 2014-2018, we evaluated 159 patients who presented positive DAT with a nonreactive eluate. Laboratory and clinical analyses were performed including HIV, HBV and HCV testing. All patients were exposed to the following drugs: Dipyrone in 63.5 %, Furosemide in 28.9 %, Metoclopramide in 34.6 % and Ondansetron in 41.5 %. Results of DAT showed IgG in 125 (78.4 %) patients and C3d in 24 (15.1 %) with reactions varying from 1+ to 4+. HIV test was positive in 10 (16.1 %) patients, HBV was positive in 3 (4.7 %) and HCV was positive in, 1 (1.5 %). There was no clinical significance when the parameters of hemoglobin, hematocrit, reticulocytes and LDH were evaluated, only a slight increase in bilirubin, especially, in patients with positive DAT reacting 3+/4+ due to IgG and C3d sensitization. Clinical evaluations showed that all patients were asymptomatic. The association of drugs with positive DAT can be a challenge to transfusion services and immunohematology reference laboratories. There was no evidence of any case of severe hemolysis with clinical repercussion through the clinical and laboratory findings analyzed with the drugs associated with positive DAT. Dipyrone and Furosemide have already been associated with DIHA but there are no studies reporting the association of Metoclopramide and Ondansetron with DIHA.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Drug-induced immune hemolytic anemia is a rare condition that occurs primarily because of drug-induced antibodies, either dependent or independent and positive direct antiglobulin test. Our aim was to evaluate the association of positive DAT with nonreactive eluate and DIHA.
MATERIALS AND METHODS METHODS
From 2014-2018, we evaluated 159 patients who presented positive DAT with a nonreactive eluate. Laboratory and clinical analyses were performed including HIV, HBV and HCV testing. All patients were exposed to the following drugs: Dipyrone in 63.5 %, Furosemide in 28.9 %, Metoclopramide in 34.6 % and Ondansetron in 41.5 %.
RESULTS RESULTS
Results of DAT showed IgG in 125 (78.4 %) patients and C3d in 24 (15.1 %) with reactions varying from 1+ to 4+. HIV test was positive in 10 (16.1 %) patients, HBV was positive in 3 (4.7 %) and HCV was positive in, 1 (1.5 %). There was no clinical significance when the parameters of hemoglobin, hematocrit, reticulocytes and LDH were evaluated, only a slight increase in bilirubin, especially, in patients with positive DAT reacting 3+/4+ due to IgG and C3d sensitization. Clinical evaluations showed that all patients were asymptomatic.
CONCLUSIONS CONCLUSIONS
The association of drugs with positive DAT can be a challenge to transfusion services and immunohematology reference laboratories. There was no evidence of any case of severe hemolysis with clinical repercussion through the clinical and laboratory findings analyzed with the drugs associated with positive DAT. Dipyrone and Furosemide have already been associated with DIHA but there are no studies reporting the association of Metoclopramide and Ondansetron with DIHA.

Identifiants

pubmed: 33277206
pii: S1473-0502(20)30338-4
doi: 10.1016/j.transci.2020.103015
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

103015

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Cristiane da Silva Rodrigues de Araújo (CDSR)

Faculdade de Medicina, Universidade de Passo Fundo, Passo Fundo, RS, Brazil; Serviço de Hemoterapia do Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil. Electronic address: crisrodrigues@upf.br.

Bruna Accorsi Machado (BA)

Serviço de Hemoterapia do Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil.

Tamaris Fior (T)

Acadêmicos de medicina da Faculdade de medicina, Universidade de Passo Fundo, Passo Fundo, RS, Brazil.

Júlia Mognon Mattiello (JM)

Acadêmicos de medicina da Faculdade de medicina, Universidade de Passo Fundo, Passo Fundo, RS, Brazil.

Mosseli Meinhart (M)

Acadêmicos de medicina da Faculdade de medicina, Universidade de Passo Fundo, Passo Fundo, RS, Brazil.

Pillar Bortolotti (P)

Acadêmicos de medicina da Faculdade de medicina, Universidade de Passo Fundo, Passo Fundo, RS, Brazil.

Laurenlisiê Lourega Heitling Brittes (LLH)

Acadêmicos de medicina da Faculdade de medicina, Universidade de Passo Fundo, Passo Fundo, RS, Brazil.

Adriano Pasqualotti (A)

Programa de Pós-Graduação em Envelhecimento Humano, Universidade de Passo Fundo, Passo Fundo, RS, Brazil.

Lilian Castilho (L)

Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH